Pelacarsen
AssetAlso ISIS 681257, TQJ230
Antisense oligonucleotide reduces hepatic apolipoprotein(a) synthesis, lowering circulating lipoprotein(a).
- Stage
- Phase 3
- Modality
- Oligonucleotide
- Target
- Lipid and ceramide metabolism
- 9
- Indications
- 11
- Trials
- 4
- Developers
Indications
9Acute coronary syndrome
Phase 3, Not yet recruiting, NCT07625306, clinicaltrials.gov, 14 Oct 2026
Atherosclerotic cardiovascular disease
Phase 3, Active not recruiting, NCT06875973, clinicaltrials.gov, 15 Oct 2026
Cardiovascular disease and lipoprotein
Phase 3, Active not recruiting, NCT07517263, clinicaltrials.gov, 15 Oct 2026
6 more
In the full profile
- Targets and what it contains2
- Owner and partners4
- Trials11
- Evidence for its targets3
- Competitors12
- Signals3
Every asset’s record: target, stage, trials and the evidence behind it.